Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2022 23:29 ET | Source: Bragar Eagel & Squire

RADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the Firm

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
September 13, 2019 18:03 ET | Source: Radius Health Inc.

Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting

WALTHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience,...
April 17, 2019 08:00 ET | Source: Radius Health Inc.

Radius Health to Present Two Posters at AACE 2019 Annual Meeting

WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
March 23, 2019 12:45 ET | Source: Radius Health Inc.

Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting

-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies...
September 24, 2018 08:00 ET | Source: Radius Health Inc.

Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing...
March 17, 2018 12:30 ET | Source: Radius Health Inc.

Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting

WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
March 12, 2018 16:30 ET | Source: Radius Health Inc.

Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
March 25, 2013 14:15 ET | Source: LaVoie Health Science

LAVOIE GROUP WINS SILVER AWARD IN THE 26th ANNUAL MERCURY EXCELLENCE AWARDS COMPETITION FOR REBRANDING RADIUS HEALTH, INC.

Cambridge, MA, March 25, 2013 (GLOBE NEWSWIRE) -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), a firm with a proven track record of building value for health science innovations through...